LRRK2 and essential thrombocythemia: The results from this study show that the odds ratios (OR) for both variants appear to be higher in ET (R1398H OR = 0.91, 95% CI = 0.71–1.17, p = 0.46; N551K OR = 0.89, 95% CI = 0.69–1.15, p = 0.37) compared to PD5 (R1398H OR = 0.86, 95% CI = 0.77–0.97; N551K OR = 0.80, 95% CI = 0.69–0.93), suggesting that a protective trend for both LRRK2 variants may be present in ET, but not high enough to reach statistical significance.